Aβ peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine.: Physiological implications and relevance for Alzheimer's disease

被引:35
作者
Agnati, L. F.
Genedani, S.
Leo, G.
Forni, A.
Woods, A. S.
Filaferro, M.
Franco, R.
Fuxe, K.
机构
[1] Univ Modena & Reggio Emilia, Physiol Sect, Dept Biomed Sci, I-41100 Modena, Italy
[2] Univ Modena & Reggio Emilia, Pharmacol Sect, Dept Biomed Sci, I-41100 Modena, Italy
[3] Univ Modena & Reggio Emilia, Dept Chem, I-41100 Modena, Italy
[4] IRCCS San Camillo, Venice, Italy
[5] Natl Inst Drug Abuse, Dept Hlth & Human Serv, Baltimore, MD USA
[6] Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain
[7] Karolinska Inst, Dept Neurosci, Stockholm, Sweden
关键词
beta-amyloid peptides; homocysteine; volume transmission; pain threshold; Alzheimer's disease;
D O I
10.1007/s00702-006-0564-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Amyloid peptides (A beta) can operate as volume transmission (VT) signals since they are continuously released from cells of the central nervous system and diffuse in the extra-cellular space of the brain. They have both regulatory and trophic functions on cellular networks. In agreement with A beta regulatory actions on glial-neuronal networks, the present paper reports new findings demonstrating that intrastriatal injections of A beta peptides reduce striatal tyrosine hydroxylase, increase striatal GFAP immunoreactivities and lower pain threshold in experimental rats. Furthermore, it has been demonstrated that exogenous homocysteine (Hcy) binds A beta(1-40) favouring its beta-sheet conformation both in vitro and in vivo and hence the formation of beta-fibrils and development of neurotoxicity. Thus, the hypothesis is discussed that A beta peptides represent crucial VT-signals in the brain and their action is altered by dysmetabolic signals such as high Hcy extra-cellular levels, known to be an important risk factor for Alzheimer's disease.
引用
收藏
页码:21 / 31
页数:11
相关论文
共 50 条
[1]   THE CONCEPT OF TROPHIC UNITS IN THE CENTRAL-NERVOUS-SYSTEM [J].
AGNATI, LF ;
CORTELLI, P ;
PETTERSSON, R ;
FUXE, K .
PROGRESS IN NEUROBIOLOGY, 1995, 46 (06) :561-574
[2]  
Agnati LF, 2000, PROG BRAIN RES, V125, P3
[3]   Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease [J].
Agnati, LF ;
Leo, G ;
Vergoni, AV ;
Martínez, E ;
Hockemeyer, J ;
Lluis, C ;
Franco, R ;
Fuxe, K ;
Ferré, S .
BRAIN RESEARCH BULLETIN, 2004, 64 (02) :155-164
[4]   Studies on homocysteine plasma levels in Alzheimer's patients.: Relevance for neurodegeneration [J].
Agnati, LF ;
Genedani, S ;
Rasio, G ;
Galantucci, M ;
Saltini, S ;
Filaferro, M ;
Franco, R ;
Mora, F ;
Ferré, S ;
Fuxe, K .
JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (01) :163-169
[5]  
AGNATI LF, 1986, IMMUNOCYTOCHEMISTRY, P205
[6]  
AGNATI LF, 1985, QUANTITATIVE NEUROAN, P91
[7]   The role of dopamine in the nucleus accumbens in analgesia [J].
Altier, N ;
Stewart, J .
LIFE SCIENCES, 1999, 65 (22) :2269-2287
[8]  
[Anonymous], 1998, Practical nonparametric statistics
[9]   Amyloid-β:: a chameleon walking in two worlds:: a review of the trophic and toxic properties of amyloid-β [J].
Atwood, CS ;
Obrenovich, ME ;
Liu, TB ;
Chan, H ;
Perry, G ;
Smith, MA ;
Martins, RN .
BRAIN RESEARCH REVIEWS, 2003, 43 (01) :1-16
[10]   Parallel "pain" pathways arise from subpopulation of primary afferent nociceptor [J].
Braz, JM ;
Nassar, MA ;
Wood, JN ;
Basbaum, AI .
NEURON, 2005, 47 (06) :787-793